NasdaqCM - Nasdaq Real Time Price ? USD Vaccinex, Inc. (VCNX) Follow Compare 2.6000 +0.1600 (+6.56%) At close: October 16 at 4:00 PM EDT 2.5200 -0.08 (-3.08%) Pre-Market: 8:00 AM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, announced today the entry into definitive agreements for the immediate exercise of outstanding warrants to purchase an aggregate of 1,067,492 shares of common stock (the “Existing Warrants”) a GlobeNewswire ? 28 days ago VCNX +6.56% Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership Company reviews goals and significance of the study and outlines development strategy in Mild Cognitive Impairment due to Alzheimer’s diseaseROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer’s disease. Our Company recently announced positive results of the phase 1b/2 study of its lead product, pepinemab, in early stages of Alzheimer’s disease (AD). The GlobeNewswire ? 2 months ago VCNX +6.56% Vaccinex’s Phase Ib/II trial for Alzheimer’s treatment hits primary endpoint The positive topline results demonstrated no serious treatment emergent adverse events. Clinical Trials Arena ? 2 months ago VCNX +6.56% Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease Results affirm expectation of a novel mechanism of action targeting astrocyte activation to delay progression of Alzheimer’s disease from early stage Mild Cognitive Impairment Findings echo previous phase 2 results in Huntington’s disease based on similarities to neuroimmune pathology in Alzheimer’s ROCHESTER, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering treatment of Alzheimer’s disease (AD) with anti-Semaphorin 4D (SEMA GlobeNewswire ? 2 months ago VCNX +6.56% Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024 Pepinemab is believed to block astrocyte reactivity, a key pathology driving Alzheimer’s progressionROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present topline data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study of pepinemab treatment for Alzhei GlobeNewswire ? 2 months ago VCNX +6.56% Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation,believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that the last pati GlobeNewswire ? 4 months ago VCNX +6.56% Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update Last patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced financial results for the first quarter ended March 31, 2024, and prov GlobeNewswire ? 4 months ago VCNX +6.56% Vaccinex Reports 2023 Financial Results and Provides Corporate Update Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024 Company raised $17.9 million of new financing during Q4 2023 and Q1 2024 ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the fourth quarter ended December 31, GlobeNewswire ? 6 months ago VCNX +6.56% Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer through the inhibition of SEMA4D, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 193,000 shares of its common stock in a registered direct offering together with warrants to purchase up GlobeNewswire ? 6 months ago VCNX +6.56% Vaccinex Announces Multiple New Agreements for Access to ActivMAb? Antigen Virus Technology Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb? Drug Discovery Platform ActivMab? platform enables the discovery and development of high value antibodies against challenging multi-pass membrane targets ROCHESTER, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer through the inhibition of SEMA4D, announces that it has entered GlobeNewswire ? 7 months ago VCNX +6.56% Vaccinex, Inc. Announces Reverse Stock Split ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it will effect a 1-for-14 reverse stock split of its issued common stock, effective at 5:00 p.m. Eastern Time on Monday, February 19, 2024. Beginning Tuesday, February 20, 2024, the Company's common stock will trade on a split-adjusted b GlobeNewswire ? 7 months ago VCNX +6.56% Steven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex Inc Point72 Asset Management, led by renowned investor Steven Cohen (Trades, Portfolio), has recently initiated a position in Vaccinex Inc (NASDAQ:VCNX), a biotechnology company focused on cancer and neurodegenerative disease treatment. On February 6, 2024, the firm acquired 1,631,648 shares of Vaccinex Inc, marking a new holding in its investment portfolio. The shares were purchased at a price of $0.5863 each, reflecting a significant move by the firm into the biotech sector. GuruFocus.com ? 7 months ago VCNX +6.56% Vaccinex Announces Pricing of $3.7 Million PIPE Financing ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced it has priced a $3.7 million private placement transaction with a lead investment from a major new investor alongside significant participation from existing investors, includin GlobeNewswire ? 8 months ago VCNX +6.56% Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule Company Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer’s Disease on Schedule to Complete Treatment in June 2024 ROCHESTER, N.Y., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer, previously reported that on October 10, 2023 it was advised by Nasdaq that the Company was no longer in comp GlobeNewswire ? 10 months ago VCNX +6.56% Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new financing during Q3 and early October 2023. ROCHESTER, N.Y., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial r GlobeNewswire ? 10 months ago VCNX +6.56% Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting Pepinemab, anti-SEMA4D blocking antibody, appears to enhance clinical activity of immune checkpoint inhibitors via induction of highly organized tertiary immune structures in tumors of patients with head and neck cancer and melanomaROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two presentations at the 38th Annual Meeting of the Society for Immunotherapy GlobeNewswire ? 11 months ago VCNX +6.56% Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient bloodROCHESTER, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, today reports novel findings for its lead product, pepinemab, in a highlighted podium presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, MA. Vaccinex has previously re GlobeNewswire ? 11 months ago VCNX +6.56% Performance Overview Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return VCNX S&P 500 YTD -71.86% +22.49% 1-Year -82.31% +35.00% 3-Year -99.39% +30.66%
